Study touts targeted chemotherapy delivery method using “chicken feather” protein
Pharmaceutical Technology
MAY 29, 2024
A team at King’s College London has developed a “drug delivery cage” that can be filled with chemotherapy drugs.
Denali Therapeutics gets grant for polypeptides targeting transferrin receptor for brain delivery
Pharmaceutical Technology
APRIL 18, 2024
Explore the groundbreaking patent (Publication Number: US11912778B2) outlining a method for creating variant polypeptides that bind to the transferrin receptor protein, revolutionizing targeted drug delivery to the brain.
Drug Delivery 
130
130 Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
New protein imaging method paves way for next generation biomaterials and tissue analysis
Scienmag
NOVEMBER 17, 2020
Scientists have established a new method to image proteins that could lead to new discoveries in disease through biological tissue and cell analysis and the development of new biomaterials that can be used for the next generation of drug delivery systems and medical devices.
Protein 67
67 
Oral Protein / Peptide-based Drugs: Addressing Key Unmet Needs Across Disease Indications
Roots Analysis
MARCH 2, 2022
Orally administrable protein / peptide-based therapeutics offer several advantages including, effective treatment of numerous clinical conditions and degenerative disorders. Over 40 oral drug delivery technologies have been designed so far. Pipeline Overview of Oral Peptide and Protein-based Therapeutics.
Protein 52
52 
Are All Excipients Truly Inert? Maybe Not, Suggests New Study
XTalks
JULY 28, 2020
Excipients can take many forms, such as bulking agents, binders, coatings and colourants, and they are chosen based on their ability to aid in drug delivery, administration and even in pill identification and prevention of counterfeiting.
Protein 103
103 
Oral COVID-19 vaccine beckons, as ImmunityBio licenses iosBio tech
pharmaphorum
JANUARY 12, 2021
“As we see multiple mutations in the SARS-CoV-2 spike protein, there is an urgent need for a vaccine that not only offers immediate protection but also activates T-cells to clear the virus,” he said. ImmunityBio’s vaccine design drives both antibody and T-cells to the spike (S) protein and nucleocapsid (N) protein.
Licensing 119
119 
Going big: How cartridges are making large-volume, high-dose subcutaneous autoinjectors a reality
Pharmaceutical Technology
APRIL 16, 2023
But with the advent of injection site absorption enhancers, drug delivery device innovations, as well as the recent primary container options, the practical subcutaneous self-administration of large-volume parenterals is becoming possible. National Library of Medicine – Silicone Oil Induced Aggregation of Proteins 4.
Protein 130
130 
Restructuring announced at ReNeuron as another CEO resigns
pharmaphorum
JANUARY 3, 2023
The change at the top comes as ReNeuron is in the throes of a pivot in its business after years of stuttering progress with stem cell programmes and a perennial shortage of operating cash, with the company announcing in July it would concentrate efforts on a proprietary exosome drug delivery platform.
Considerations for Neuroscience Trials with Intrathecal Delivery and Other Methods of Direct CNS Administration
XTalks
AUGUST 30, 2022
One of the biggest challenges with developing therapies to treat CNS disorders is the delivery of systemically administered investigational products (IPs) to the brain, which is limited by the blood-brain barrier. Some methods of direct CNS administration include intrathecal, intraparenchymal and intracerebroventricular (ICV) delivery.
Trials 83
83 
mRNA Therapeutics and mRNA Vaccines Industry: Current Scenario and Future Trends
Roots Analysis
MARCH 16, 2023
It is important in the process of protein synthesis because mRNA is responsible for transferring genetic information from DNA to ribosomes, which then decodes the genetic information into a protein. In the last few years, researchers have become interested in using in vitro transcribed (IVT) mRNA as a drug delivery agent.
Vaccination 52
52 
Altimmune ditches nasal COVID vaccine on weak trial data
pharmaphorum
JUNE 30, 2021
AdCOVID was able to stimulate antibodies that bound the SARS-CoV-2 spike protein and were able to neutralise the virus, but not in sufficient quantities and in too few patients.
Vaccination 98
98 
Introduction To Exosome Therapeutics
Roots Analysis
MARCH 8, 2023
Over time, various research studies have demonstrated the potential of exosomes ( membrane bound extracellular vesicles) in disease diagnosis, drug delivery and therapeutic applications. Targeted Drug Delivery: Ability to cross blood brain barrier cause lesser systemic effects and low toxicity.
RNA 52
52 
Conjugation and Labeling of Molecules: A Burgeoning Approach in Therapeutics Development and Molecular Imaging
Roots Analysis
SEPTEMBER 13, 2023
Conjugation is the process of formation of a single, stable hybrid, wherein one of the entities is a molecule, such as protein, antibody, peptide and small molecule. Bioconjugation is a subset of conjugation where one of the entity is a biomolecule, such as protein or an antibody.
Development 40
40 
Autoinjector: Empowering The Healthcare Industry
Roots Analysis
MAY 24, 2024
In the dynamic landscape of the healthcare sector, the evolution of drug delivery systems plays a significant role in transforming the management of chronic diseases. These devices reduce injection anxiety, and are useful for patients who prefer a hands-free drug delivery experience.
CytoDel Announces Pre-Clinical Data on Cyto-111 as Antidote to Botulinum Neurotoxin (BoNT) Published in Science Translational Medicine
The Pharma Data
JANUARY 6, 2021
Based on Dr. Ichtchenko’s hypothesis that the C1 ad delivery vehicle previously reported could be used to transport therapeutic proteins into the neuronal cytosol, researchers led by Dr. Ichtchenko developed and tested a potential treatment for botulism based on intracellular inhibition of the BoNT subtype A1 light chain metalloprotease (LC/A1).
Medicine 52
52 
Alnylam sues Pfizer, Moderna over COVID-19 vaccines
pharmaphorum
MARCH 17, 2022
.” Both Pfizer’s BioNTech-partnered Comirnaty and Moderna’s SpikeVax vaccines use LNPs to carry mRNA coding for the SARS-CoV-2 spike protein. After dosing, the LNPs deliver the mRNA sequence into cells, which is then used by cellular machinery to manufacture the viral protein and stimulate an immune response.
Vaccination 52
52 
Exosomes: A Trending Term in Therapeutic Domain
Roots Analysis
MARCH 11, 2022
Exosomes are known to have some unique functions, such as their ability to alter recipient cell bioactivities, acting like intercellular messengers and also having therapeutic potential in disease diagnostics as well as targeted drug delivery. II are involved in sorting these ubiquitinated proteins. Both ESCRT?I I and ESCRT?II
Growing Demand for Oligonucleotides Proposes Shedload of Opportunities for Contract Manufacturers
Roots Analysis
FEBRUARY 18, 2022
In the 20 th century, major research went into discovery of a therapeutic class with the primary purpose of interfering with the RNA expression linked to disease causing proteins, nowadays classified as oligonucleotides. Our Social Media Platform. Web: [link]. LinkedIn: [link]. Twitter: [link]. Medium: [link]. Pinterest: [link].
John McHutchison joins the Board of Evox Therapeutics
The Pharma Data
JANUARY 17, 2021
Evox uses its proprietary DeliverEX technology to modify exosomes using various molecular engineering, drug loading, and targeting strategies to facilitate targeted drug delivery to organs of interest, including the brain and the central nervous system.
Life Science 40
40 
BetterLife Engages Eurofins Discovery for its Next Generation Psychedelics 2-bromo-LSD FDA IND-enabling Pharmacology Studies
The Pharma Data
JANUARY 27, 2021
Utilizing drug delivery platform technologies, BetterLife is refining and developing drug candidates from a broad set of complementary interferon-based technologies which have the potential to engage the immune system to fight virus infections, such as the coronavirus disease (COVID-19) and human papillomavirus.
In-Vitro 52
52 
FDA accepts application for Roche’s Port Delivery System with ranibizumab (PDS) for treatment of neovascular or “wet” age-related macular degeneration (nAMD)
The Pharma Data
JUNE 26, 2021
About Port Delivery System with ranibizumab (PDS) PDS is a permanent refillable eye implant, approximately the size of a grain of rice, which is designed to continuously release a customised formulation of ranibizumab into the eye over time. 13 PDS contains a customised formulation of ranibizumab not approved by regulatory authorities.
Gelteq IPO: Supporting Gel Technology for Oral Drug Delivery
XTalks
NOVEMBER 6, 2024
Gelteq centers its technology on a proprietary, customizable gel platform designed for precise drug delivery, supporting prescription drugs, nutraceuticals, pet care and sports supplements. Priced at $4.0
Drug Delivery 104
104 
Crescita Announces Licensing Agreement for Pliaglis; in China
The Pharma Data
NOVEMBER 4, 2020
It is the first such project in China to develop recombinant mussel adhesive protein by gene recombination, fermentation engineering technology and specific enzyme catalytic fusion technology, and is expected to become a leader in this field. For additional information, please visit [link].
Licensing 40
40 
Liposome: A Novel Drug Delivery System
Roots Analysis
AUGUST 8, 2023
Furthermore, a wide variety of drugs and macromolecules, including DNA , proteins, and imaging agents, can be encapsulated in liposomal vesicles due to their unique ability to entrap both lipophilic and hydrophilic substances. The various therapeutic applications of liposomes in drug delivery have been highlighted in the figure.
Nanoparticle Formulation: A Paradigm Shift towards Novel Drug Delivery
Roots Analysis
OCTOBER 2, 2023
Owing to their unique size and physicochemical properties ( surface roughness, surface area, surface energy, crystal structure and shape ), nanoparticles can be widely used as a contrasting agent in medical imaging, a vesicle to cross the blood-brain barrier and a carrier for targeted delivery of genes / drugs, proteins, vaccines and antibiotics.
Subcutaneous Medications and Drug Delivery Systems
Roots Analysis
FEBRUARY 26, 2024
Given the robust pipeline of biologics, which include monoclonal antibodies, vaccines and other protein-based therapeutic products, subcutaneous medications are being investigated for various clinical candidates across different phases of development. You can also download the SAMPLE REPORT on subcutaneous medications by Roots Analysis.
Subcutaneous Biologics: The Unmet Requirement in the Pharmaceutical Space
Roots Analysis
MARCH 21, 2022
However, several drug delivery devices that enable patients to self-administer their respective medications are now available. Subcutaneous drug delivery systems – the helping hand for patients. The emergence of safer and patient-friendly devices is acting as a strong enabler for subcutaneous delivery of therapeutics.
Nasal Delivery of mRNA Therapeutics: A Novel Approach to Drug Development for Asthma
XTalks
OCTOBER 1, 2024
mRNA therapies work by instructing cells to produce specific proteins that can enhance the body’s natural defenses or correct deficiencies. ETH47, Ethris’ investigational mRNA therapeutic, is designed to address this vulnerability by encoding for interferon lambda, a crucial protein in the immune response. “By
Development 52
52 
RNA Therapeutics: A Novel Approach to Treating Diseases
Roots Analysis
OCTOBER 22, 2023
Coding RNAs include messenger RNA (mRNA) and short interfering RNA (siRNA), which encode proteins and silence gene expression, respectively. ASOs are short single-stranded nucleotides that bind to specific messenger RNAs and prevent the production of a particular protein.
RNA 40
40 
JS Bio and Etta Biotech Advancing Strategic Partnership
The Pharma Data
JANUARY 16, 2021
Etta Biotech”), to set up a high titer transient protein expression platform for high quality protein production using JS Bio’s transient transfection media. JS Bio becomes the exclusive cell culture supplier for Etta Biotech’s transient transfection high titer protein expression platform. JS Bio’s parent company.
Protein 52
52 
Pair of R&D updates bolster GSK ahead of investor meeting
pharmaphorum
JUNE 22, 2021
GlaxoSmithKline (GSK) has reported encouraging data for its COVID-19 antibody sotrovimab, and an alliance with Halozyme to develop a new generation of long-acting HIV drugs, as it prepares to give a much-anticipated update to shareholders tomorrow. The post Pair of R&D updates bolster GSK ahead of investor meeting appeared first on.
Antibody 52
52 
FDA Approves J&J’s Darzalex Faspro for Rare Light Chain Amyloidosis
The Pharma Data
JANUARY 17, 2021
It is co-formulated with recombinant hyaluronidase PH20 (rHuPH20), Halozyme’s ENHANZE drug delivery technology. AL amyloidosis is a blood disorder associated with an abnormal protein that causes deterioration of vital organs, especially the heart, kidneys and liver.
FDA Approval 52
52 
Boehringer buys Abexxa, bolstering its immuno-oncology pipeline
pharmaphorum
SEPTEMBER 22, 2021
Its lead project is a T-cell receptor (TCR)-like antibody against an HLA molecule associated with intracellular protein NKG2A, an immune checkpoint. Inhibiting NKG2A is thought to restore the activity of natural killer cells and T cells against cancer. Boehringer’s activity in this area hasn’t all been additive though.
Antibody 92
92 
Biopharmaceutical Excipient Manufacturing – Current Scenario and Future Trends
Roots Analysis
MARCH 13, 2022
In the last decade alone, the annual number of approvals of biopharmaceuticals (including monoclonal antibodies, recombinant proteins, vaccines and gene therapies), by the US FDA, have steadily risen. Over the years, the rising popularity of biologics has led to a paradigm shift in the healthcare industry. Our Social Media Platform.
mRNA Synthesis: ManufacturingProcess of Modern Revolutionary Molecule
Roots Analysis
FEBRUARY 13, 2023
Messenger ribonucleic acid (mRNA) is a single-stranded molecule, which carries coding sequence and plays a prominent role in protein synthesis. It transfers genetic information form to DNA to ribosomes, a specialized structure, or organelle, which decodes genetic information into a protein.
TLC Announces Full Patient Enrollment in EXCELLENCE Trial of TLC599 for Osteoarthritis PainOn-schedule completion of enrollment despite COVID-19 pandemic; unique trial design evaluates safety and efficacy of single & repeat doses
The Pharma Data
DECEMBER 27, 2020
Current intraarticular anti-inflammatory treatments for OA have potentially toxic side effects and may lead to the destruction of cartilage filler proteins. About TLC599. An in vivo toxicity study by staining of the cartilage showed TLC599 to be cartilage sparing compared to current treatments.
Trials 40
40 
Biopharmaceutical Excipient Manufacturing Market: Current Scenario and Future Potential
Roots Analysis
MARCH 9, 2022
In the last decade alone, the annual number of approvals of biopharmaceuticals (including monoclonal antibodies, recombinant proteins, vaccines, and gene therapies), by the US FDA, have steadily risen. Over the years, the rising popularity of biologics has led to a paradigm shift in the healthcare industry.
The Promising Potential of Pulsed Field Ablation for Cardiac Rhythm Management
Roots Analysis
JANUARY 3, 2024
While numerous cardiovascular drug delivery devices and drug eluting stents are accessible for treating these conditions, treatment options for AF, including the anti-arrhythmic drugs, frequently prove ineffective.
Marketing 40
40 
Striving to Deliver Better Outcomes: Janssen to Showcase Commitment to.
The Pharma Data
AUGUST 31, 2021
Additionally, Janssen will present an update on the Phase 3 SunRISe-2 trial evaluating an investigational intravesical drug delivery system, TAR-200, in combination with the programmed cell death receptor-1 (PD-1) inhibitor cetrelimab in muscle-invasive urothelial carcinoma (Abstract # MP13-17). [1]. About TAR-200.
Bayer strengthens gene therapy portfolio with lipid nanoparticle technology from Acuitas Therapeutics
The Pharma Data
JUNE 7, 2023
a biotechnology company specializing in the development of lipid nanoparticle (LNP) delivery systems for molecular therapeutics. Acuitas’ LNP technology will support Bayer’s in vivo gene editing and protein replacement programs by specifically delivering RNA payloads to the desired target organ, the liver.
Gene Therapy 40
40 
Arexvy Shows Strong Efficacy Over Three RSV Seasons in New Phase III Data
XTalks
OCTOBER 11, 2024
Pfizer’s Abrysvo targets both RSV-A and RSV-B subtypes with a recombinant RSV F protein antigen, while Arexvy focuses on RSV-A alone but enhances immune response with the AS01E adjuvant. No new safety issues emerged over the course of the three seasons.
Vaccination 103
103 
The Power of Lipids: Enhancing Drug Delivery with Nanoparticles
Roots Analysis
MAY 21, 2024
LNPs comprise of a lipid bilayer that surrounds a hydrophobic core, which can be loaded with therapeutic agents ( such as drugs, genetic material and proteins ). The average size of LNPs typically ranges from 40 to 1,000 nanometers, which allows efficient cellular uptake and intracellular delivery.
Darzalex Faspro (daratumumab and hyaluronidase-fihj) Becomes the First FDA-Approved Treatment for Patients with Newly Diagnosed Light Chain (AL) Amyloidosis
The Pharma Data
JANUARY 15, 2021
Food and Drug Administration (FDA) approval of Darzalex Faspro ® (daratumumab and hyaluronidase-fihj), a subcutaneous formulation of daratumumab, in combination with bortezomib, cyclophosphamide and dexamethasone (D-VCd) for the treatment of adult patients with newly diagnosed light chain (AL) amyloidosis.[1]
FDA Approval 52
52 
Subcutaneous Biologics Market Analysis: Current Trends and Future Outlook
Roots Analysis
JANUARY 27, 2025
In order to help circumvent these disadvantages, several drug delivery devices, which enable patients to self-administer drugs through subcutaneous route are now being developed. Further, majority of the approved subcutaneous biologics are proteins.
Marketing 40
40 
Let's personalize your content